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In order to increase their predictive power, medical biomarkers can be combined into panels.
However, the lack of ready-to-use tools generating interpretable results and implementing
rigorous validation standards hampers the more widespread application of panels and their
translation into clinical practice.
The computational toolbox we present here – PanelomiX – uses the iterative combina-
tion of biomarkers and thresholds (ICBT) method. This method combines biomarkers and
clinical scores by selecting thresholds that provide optimal classiﬁcation performance. To
speed up the calculation for a large number of biomarkers, PanelomiX selects a subset of
thresholds and parameters based on the random forest method. The panels’ robustness
and  performance are analysed by cross-validation (CV) and receiver operating characteristic
(ROC) analysis.
Using 8 biomarkers, we compared this method against classic combination procedures in
the  determination of outcome for 113 patients with an aneurysmal subarachnoid haemorr-
hage. The panel classiﬁed the patients better than the best single biomarker (p < 0.005) andcompared favourably with other off-the-shelf classiﬁcation methods.
In  conclusion, the PanelomiX toolbox combines biomarkers and evaluates the perfor-
mance of panels to classify patients better than single markers or other classiﬁers. The ICBT
algorithm proved to be an efﬁcient classiﬁer, the results of which can easily be interpreted.
methods and results can often be difﬁcult to understand for
he A© 2013 T.  Introduction
he translation of panels of biomarkers into clinical practice
s principally obstructed by two critical factors [1]. Firstly,
Abbreviations: ROC, receiver operating characteristic; AUC, area un
ensitivity; SP, speciﬁcity; aSAH, aneurysmal subarachnoid haemorrha
∗ Corresponding author. Tel.: +41 223795486.
E-mail addresses: Xavier.Robin@unige.ch (X. Robin), Natacha.Turck
atalia.Tiberti@unige.ch (N. Tiberti), Frederique.Lisacek@isb-sib.ch 
arkus.Mueller@isb-sib.ch (M. Müller).
212-9634
ttp://dx.doi.org/10.1016/j.trprot.2013.04.003
©  2013 The Authors. Published by Elsevier B.V. Open access under uthors. Published by Elsevier B.V. Open access under CC BY-NC-SA license. der the ROC curve; pAUC, partial AUC; CV, cross-validation; SE,
ge; SVM, support vector machines.
@unige.ch (N. Turck), Alexandre.Hainard@unige.ch (A. Hainard),
(F. Lisacek), Jean-Charles.Sanchez@unige.ch (J.-C. Sanchez),
non-experts; secondly, there is a general lack of robust vali-
dation steps, which are critical for the reproducibility of results
given high biological variation.
 CC BY-NC-SA license. 
 t e o m
applying the previous formula.58  t r a n s l a t i o n a l p r o
To overcome the ﬁrst issue, a combination method must
produce clear and easily interpretable results, where patient
classiﬁcation can be understood in terms of the contribu-
tion of each individual biomarker. Medical practitioners have
long been used to clinical scores, such as the Hoffer–Osmond
test to diagnose schizophrenia [2,3], or the Ranson score [4]
for the prognosis and operative management of acute pan-
creatitis. These methods were recently applied to assess the
probability of pulmonary embolism [5] and acute pancreati-
tis [6]. These types of scores have become popular because
they are clear and easy to interpret, granting access to the
intermediate results of individual sub-tests. This is in contrast
to black box classiﬁers, such as neural networks or support
vector machines (SVM), which may display high accuracy, but
which do not reveal the contribution of each individual marker
directly. While black boxes are acceptable in speciﬁc appli-
cations, they may not always be suitable in expert systems
for medical decision-making [7–9]. In contrast, many  methods
present results in a user-friendly format referred to as “white
boxes”.
Combining biomarkers is an application of statistical learn-
ing. Over the years, this ﬁeld has developed countless methods
to tackle the task. Linear or logistic regression methods deter-
mine a factor, generally multiplicative, for each biomarker
included in the panel. A straightforward interpretation of
these factors is to see them as the “weights” of inﬂuence of
the biomarkers. Methods based on decision trees also pro-
vide an easy interpretation, where one follows a sequence
of binary splits. As long as a tree contains only a fairly lim-
ited number of such decisions (or branches), these are easy
to track and to justify how a decision was reached. Decision
trees are graphically expressive (see [1]) for easier understand-
ing. Finally, in threshold-based methods, all biomarker tests
are analysed at the same time (instead of sequentially), and
the number of positive tests deﬁnes a score used for classiﬁ-
cation.
The second issue is the lack of a robust validation step.
Panel validation requires an independent test set – preferably
measured in a different laboratory – in order to compute the
panel’s true performance and avoid performance overestima-
tion due to over-ﬁtting the data during the learning process
[1]. If no independent set is available, computational meth-
ods such as cross-validation (CV) or bootstrapping allow the
simulation of such sets [10,11].
Two useful and quite common performance measures
are sensitivity (the proportion of positive patients correctly
detected by the test) and speciﬁcity (the proportion of negative
patients correctly rejected by the test), as they give clear esti-
mates of how patients are classiﬁed [1]. When no biomarker
level cut-off is preferred or pre-deﬁned, receiver operating
characteristic (ROC) analysis can be performed to weight the
trade-off between sensitivity and speciﬁcity [10]. The area
under the ROC curve (AUC) is also a very common perfor-
mance metric in medical decision-making [12], bioinformatics
[13] and statistical learning [14]. An important and often
neglected step is the panel’s performance comparison against
that of single biomarkers. A fair evaluation would process the
panel and single biomarkers with the same tools (sensitivity
and speciﬁcity or AUC) on the same independent test set or
with the same CV procedure [1]. Then performance could be i c s 1 ( 2 0 1 3 ) 57–64
compared either with McNemar’s test (for sensitivity or speci-
ﬁcity) or using ROC curves.
The methods we  propose here, which use single biomarker
thresholds as the base of their decisions, are part of
the PanelomiX software. In threshold-based combinations,
thresholds are often chosen in a univariate manner. For exam-
ple, Ranson et al. [4] selected convenient prognostic sign
cut-off values outside the range of the mean plus or minus
one standard deviation; Morrow and Braunwald [15] chose
the 99th percentile of the control distribution; Sabatine et al.
[16] used the cut-offs described in the literature. In contrast,
Reynolds et al. [17] adopted a multivariate approach and tested
many  thresholds by 10% increments. This approach takes
into account the interaction that may arise when biomarkers
are combined. PanelomiX can combine biomarkers (molecule
levels, clinical scores, etc.) in a multivariate manner. There-
fore we developed an exhaustive search algorithm to select
the optimal thresholds, and called it iterative combination
of biomarkers and thresholds (ICBT). To minimize execution
times, we  developed several approaches to reduce complex-
ity and hence increase search speed. As it has been shown to
be an efﬁcient feature selection method [11], we  used random
forest [18,19] as a ﬁltering method to reduce both the num-
ber of biomarkers and thresholds that account for the search
space size. Random forest builds a large number of decision
trees that are made slightly different by bootstrapping. In the
end, the classiﬁcation is the average prediction of all trees.
PanelomiX has already been applied to predict the outcome
of an aneurysmal subarachnoid haemorrhage (aSAH) [20] and
to assess the progression of human African trypanosomia-
sis [21]. Below, we  demonstrate the PanelomiX methodology
and performance, using 8 parameters for the determination
of outcome for patients with an aSAH.
2.  Methods
2.1.  Iterative  combination  of  biomarkers  and
thresholds  (ICBT)
2.1.1.  Combining  biomarkers
The approach adopted here is based on the ICBT method. A
threshold is deﬁned for each biomarker by an optimization
procedure deﬁned in the following sections. A patient’s score
is the number of biomarkers exceeding their threshold values.
We can write this as:
Sp =
n∑
i=1
I(Xip ≥ Ti) (1)
where Sp is the score for patient p, n is the number of biomark-
ers, Xip is the concentration of the ith biomarker in patient p,
Ti is the threshold for the ith biomarker, and I(x) is an indicator
function which takes the value of 1 for x = true and 0 otherwise.
If biomarker concentrations are higher in the control than
in the disease group, then they are multiplied by −1 beforeTo classify a patient, a threshold on the Sp score is required
and deﬁned as Ts. Patients with a score Sp ≥ Ts are positive;
negative otherwise.
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.1.2.  Selecting  the  thresholds
he list of thresholds tested in the ICBT search must be kept
hort to limit computation time. Candidate thresholds are
elected as local extrema of the ROC curve, computed with
ROC [22]. A local extremum is deﬁned as a point of local
aximal distance to the diagonal line. To construct the ROC
urve we  sort the list of biomarker values, resulting in a list
f increasing speciﬁcity (SP) and decreasing sensitivity (SE).
he threshold value Ti is a local extremum if SP[i] ≥ SP[i − 1]
nd SE[i] ≥ SE[i + 1]. Thresholds that are not local extrema will
ot lead to better classiﬁcation. Usually several thresholds are
elected as local extrema on a ROC curve.
.1.3.  Optimizing  the  panel
he combinatorial complexity of testing all combinations of
iomarkers and threshold values with ICBT can be calculated.
iven n biomarkers, and panels with up to m biomarkers, the
umber C of biomarker combinations to test, is given by:
 =
m∑
i=1
(
n
i
)
=
m∑
i=1
n!
i!(n − i)! (2)
If there are t thresholds per biomarker, formula (3) gives the
otal number I of threshold combinations to test:
 =
m∑
i=1
(
n!
i!(n − i)! t
i
)
(3)
n addition, all possible Ts from 1 to n − 1 are considered.
In a typical setup, one would test combinations of 5 or less
ut of 10 biomarkers, with 15 thresholds per biomarker. This
orresponds to 637 possible biomarker combinations to test.
he total number of possible combinations of thresholds and
iomarkers comes to 202 409 025, which is still manageable
sing current desktop computers.
In most real world applications, however, each biomarker
ill have a different number of thresholds. If T is a vector
ontaining the number of thresholds of all biomarkers in com-
ination j, a more  precise estimate is given by:
 =
C∑
j=1
(∏
Tj
)
(4)
.1.4.  Pre-ﬁltering
hen computational time becomes too long, an additional
tep is necessary to reduce the number of biomarkers and
hresholds. From the N initial biomarkers, P biomarkers are
elected (with P < N), each associated with a maximal number
f cut-offs (Q). In PanelomiX, random forest [18,19] is employed
s a multivariate ﬁlter [11]. The trees created during the pro-
ess are analysed to deduce the most frequent biomarkers and
hresholds that potentially give the most interesting combi-
ations. We  proceed by stepwise elimination. First, a random
orest with all the N biomarkers is created. The frequency with
hich each biomarker appears in tree branches is extracted
nd the N − 1 biomarkers occurring most often are kept to
uild the next random forest. These two steps are repeated
ntil the target number of P biomarkers is reached. Finally, c s 1 ( 2 0 1 3 ) 57–64 59
a last random forest is computed with P remaining biomark-
ers to determine the Q thresholds occurring most frequently
for each marker. As each tree of the random forest is com-
puted from a different set of patients, the cut-offs will differ
slightly between the decision trees of the forest. To be more
informative, the thresholds are therefore mapped to the origi-
nal ones using Euclidean distance. Thresholds are then sorted
by frequency and the Q ﬁrst thresholds of each biomarker are
selected for an exhaustive search.
2.1.5.  Code  optimization
At the programming level, the ICBT search was optimized to
run faster. First, it was implemented in the compiled pro-
gramming language Java, which typically runs much faster
than interpreted languages such as R, Perl or Python. Efﬁcient
implementation was achieved by minimizing the creation of
objects, using explicit programmatic loops instead of recur-
sion, and multithreading.
Biomarkers with missing values are ignored. Missing value
imputations must be performed before submitting the data to
PanelomiX (see [23] for an in-depth review of this topic).
2.1.6.  Cross-validation
Cross-validation is a simple and widely used computational
method to assess a classiﬁcation model’s performance and
robustness [1,10]. PanelomiX features a CV procedure for panel
veriﬁcation [10]. Its primary goal is to test panel performance
in an unbiased manner and to produce graphical diagnostic
plots for evaluating consistency and robustness. After CV, ROC
analyses are performed on the individual biomarkers and the
panel, and several plots are generated to assess the quality of
the data.
A standard, k-fold cross-validation (CV) scheme is used to
compare the different models generated. To avoid model-to-
model scoring differences and make predictions comparable
between the CV steps, which may produce panels of different
lengths with different Ts, the prediction is centred as follows:
Yp = Sp − Ts
Zp(Yp) =
{
Yp/Ts, Yp < 0
Yp/(n − Ts), Yp > 0
}
(5)
As a result, the centred vector Z of patient scores is in the
[−1;+1] interval and Ts = 0.
2.1.7.  ROC  curves
We  perform ROC analysis of the curves of both the indi-
vidual biomarkers and the panels using the pROC tool [22]
in R [24]. Three tables are generated showing AUC, sensi-
tivity, and speciﬁcity, all with conﬁdence intervals. The ﬁrst
table reports the ROC performance of single biomarkers and
their best univariate thresholds; the second table shows the
comparison of the panel with the best individual biomarker
(analysed as a panel composed of 1 biomarker, to be compa-
rable with the other panels); and the third table compares the
ICBT panel with other classic combination methods. Compar-
isons between two AUCs are performed using DeLong’s test
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Table 1 – Biomarkers and thresholds in the panel.
Biomarker H-FABP S100b Troponin I NDKA UFD-1 WFNS Age Fisher score
11.0
g/Threshold 1.11 0.51 2.33 
Unit g/l g/l g/l 
[25] and between two pAUCs using the bootstrap test [22] with
10 000 stratiﬁed replicates. The ROC curves of the CV are built
as the mean of centred predictions over the k CV folds. For the
CV of the individual biomarkers, the ICBT algorithm is applied
with n = 1 and no other modiﬁcation.
2.1.8.  Availability
Users can access a password-protected server implementing
the algorithms described in this article from the following
website: http://www.panelomix.net.
2.2.  Case  study
2.2.1.  Patients
The PanelomiX methodology was applied to a previously pub-
lished data set of 113 patients with an aSAH. The goal was to
identify patients at risk of a poor outcome six months after
an aSAH – those who would require speciﬁc healthcare man-
agement. Detailed results of the study are reported in [20]. We
will only outline the features relevant to panel analysis here.
2.2.2.  Panel  analysis
As described above, panels were generated with ﬁve proteins
(H-FABP, S100, Troponin I, NKDA and UFD-1) and three clinical
factors (WFNS, modiﬁed Fisher score and age). A ten-fold CV
was carried out to assess the performance of the biomarkers,
the panels and their stability.
2.2.3.  Comparison  with  standard  methods
The results obtained with PanelomiX were compared with
other methods: logistic regression with the glm package and
step-wise elimination functions; support vector machines
(SVM) using the kernlab package [26] (nu-regression with lin-
ear kernel); and recursive partitioning decision trees using
the rpart package [27,28]. To be consistent with the Pan-
elomiX method, both SVM and decision tree feature sets
were determined using an exhaustive search of all possible
combinations. Additionally, the predictions were centred as
described above.
2.2.4.  ROC  sample  size  computation
The sample size required for a statistically signiﬁcant com-
parison of two ROC curves was calculated according to
Obuchowski and McClish [29], where variances and covarian-
ces of the ROC curves were computed using bootstrapping
[30].
3.  Results  and  discussion
3.1.  Training  the  panelsThe PanelomiX methodology was applied to the 113-patient
cohort of the aneurysmal subarachnoid haemorrhage study
[20] in order to deﬁne the combination of 8 biomarkers with8 271.48 1.5 72.5 2.5
l g/l N/A Years N/A
the best classiﬁcation accuracy. Using the whole cohort as a
training set, but without CV, a panel containing 8 biomarkers
(i.e. the 5 proteins and the 3 clinical parameters) was found
using the thresholds given in Table 1. The panel’s performance
was evaluated using two methods: threshold sensitivity and
speciﬁcity, and area under the ROC curve (AUC). On the train-
ing set this panel showed 95% sensitivity and 90% speciﬁcity,
corresponding to an AUC of 95%.
3.2.  Cross-validation
Ten-fold CV was repeated 10 times with 10 random selections
of the folds. The four plots that allowed us to evaluate the
stability of the panel with CV are shown in Fig. 1.
- The marker selection frequency plot shows the frequency of
selection of each biomarker variable in the panels trained
in k CV folds. A biomarker with a 100% frequency is selected
in all panels; the frequency is weighted. If one step of the CV
yields several panels, then each of them contributes less to
the ﬁnal frequency compared to panels which were unique
in a CV fold. Fig. 1A shows that all eight biomarkers selected
in the training panel are selected between 88% (Fisher score)
and 100% (NDKA, H-FABP, S100b, WFNS) of the CV panels.
- The panel size frequency plot displays the number of biomark-
ers in the panels, weighted as described above. Fig. 1B shows
that 69% of the CV panels contained 8 biomarkers. In 27%
of the CV panels 7 biomarkers were selected, and in the 4%
remaining only 6 biomarkers were selected. No panels con-
taining 5 or fewer biomarkers were generated during the CV
procedure.
- The panel Ts frequency plot shows the score Ts, determining
how many  biomarkers must be positive in a patient for the
panel to be positive, weighted as described above. In Fig. 1C,
Ts = 3 in 25% of the panels, Ts = 5 in 4% and Ts = 4 in the rest
of the cases.
-  The threshold stability plot represents biomarkers on the x-
axis and thresholds (as a rank, not an absolute value) of
all panels found in the CV on the y-axis. Each panel cor-
responds to a line joining its constituting set of biomarkers
and thresholds. Fig. 1D shows that S100b had a very sta-
ble threshold, unlike NDKA or UFD-1 that showed a larger
variation. For H-FABP, 3 clusters appeared, corresponding
to thresholds of 0.61 g/l (rank 22), 1.11 g/l (rank 33) and
4.51 g/l (rank 84). This indicates that the H-FABP cut-off at
5.9 g/l, found in the training panel, is not as robust as the
cut-off at 0.51 g/l found for S100b.
3.3.  Performance  evaluationA ROC analysis was performed as described in the previ-
ous section (Fig. 2). The panel found using the training set
was plotted together with that found using CV and the sepa-
rate biomarkers (see next section). Using CV, panels displayed
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Fig. 1 – Cross-validation plots. (A) Marker selection frequency plot; (B) panel size frequency plot; (C) panel Ts frequency plot;
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5.9% sensitivity and 88.9% speciﬁcity, corresponding to an
UC of 88.6%.
Fig. 3 shows the performance of PanelomiX on the training
et and using CV for panels of different sizes. Using CV, pan-
ls with 7 biomarkers are optimal, with an AUC (88.8%) slightly
igher than panels of 8 (88.6%). However, the difference is min-
mal and it is difﬁcult to determine the signiﬁcance of this
hange. This indicates that the level of over-ﬁtting induced by
CBT is low and that classiﬁcation with panels is an improve-
ent on single biomarkers.
.4.  Comparison  with  single  biomarkers
ig. 3 shows that individual biomarkers are slightly over-ﬁtted
nd display a lower AUC using CV (71%) than on the training
ample (73%). To perform a fair comparison, PanelomiX com-
ared both panel and single biomarkers under CV. To that end,
e used the ICBT algorithm where the threshold is chosen on
he training set, and applied to the test set.
The two best biomarkers, H-FABP and WFNS, are plotted
ith ICBT in Fig. 2. The CV results (dotted lines) show thatpanels of 8 biomarkers, with an AUC of 89%, are superior to the
individual biomarkers with AUCs of 76% (p = 0.003) for WFNS
and 68% (p = 1.5 × 10−6) for H-FABP.
3.5.  Comparison  with  established  methods
PanelomiX was compared with three established methods
of biomarker analysis: logistic regression, SVM and deci-
sion trees (recursive partitioning). The results are shown in
Fig. 4. PanelomiX displayed the best AUC (89%), slightly but
not signiﬁcantly higher than SVM (82%, p = 0.20) and logistic
regression (81%, p = 0.13). Only recursive partitioning decision
trees had a signiﬁcantly lower AUC of 77% (p = 0.03). Compared
with SVM, PanelomiX gives results with a very similar classi-
ﬁcation performance, but in a way that is easier to interpret.
3.6.  Evaluation  of  random  forest  pre-processingClassiﬁcation performance was assessed both with and with-
out the initial pre-processing step using random forest. The
results are shown in Fig. 5. Pre-ﬁltering made no difference
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Fig. 2 – ROC curves. Solid lines represent the performance
on the training set, dotted lines the CV. Red: panel of 8
markers; green: WFNS; blue: H-FABP. (For interpretation of
the references to colour in this artwork, the reader is
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Fig. 4 – ROC curves showing the comparison with other
standard combination methods. Black: PanelomiX; blue:
logistic regression; green: SVM; red: recursive partitioning.
(For interpretation of the references to colour in this
artwork, the reader is referred to the web version of the
article.)
1
0
0referred to the web version of the article.)
in classiﬁcation efﬁciency using one biomarker. However, as
we tested panels of 2–6 biomarkers, it consistently led to
decreased AUC. The diagnostic plots (data not shown) indi-
cated a selection of panels with fewer biomarkers when
features were selected with random forest; this suggests that
the tree-based feature selection is not optimal when com-
bined with a threshold-based classiﬁcation. With 7 and 8
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Fig. 3 – Performance of training (solid line) and CV (dashed
line) as a function of the number of markers allowed in the
panel.
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Fig. 5 – Performance without (solid line) and with random
forest pre-processing (dashed line) as a function of the
number of markers allowed in the panel.
biomarkers, the effect was reversed and the classiﬁcation was
even slightly improved when all 8 biomarkers were selected.
These results suggest that the pre-processing with random
forest should be applied with care, and that a few more  fea-
tures than simply the target number should be kept in mind.
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Table 2 – Execution time for increasingly large panels on an Intel Core2 Quad CPU Q9550 at 2.83 GHz processor. This table
shows a simple training, and CV (N = 10, K = 10).
Panel size, n 1 2 3 4 5 6 7 8
2 s 8.2 s 1.6 min 11 min 49 min 2.0 h
0 min
6 min
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Cross-validation 25 s 32 s 2.
Cross-validation with random forest 1.1 min 1.4 min 1.
.7.  Computation  time
s stated earlier, all the combinations of all 8 biomarkers and
hresholds can be tested. Table 2 shows the processing time to
rain a single panel and to perform 10 ten-fold CVs. The CV of
anels of up to 8 biomarkers took slightly less than 6 days to
omplete on a 4-core machine. Feature selection with random
orest made computation 70 times faster with 8 markers, mak-
ng it possible to test panels much larger than 8 biomarkers
hen necessary.
.  Conclusions
n this paper, we proposed an algorithmic solution for com-
ining several biomarkers into a panel using the ICBT method
ased on an iterative combination of biomarkers and thresh-
lds. We  demonstrated that the deﬁnition of an optimal panel
hrough exhaustive search is feasible with current comput-
rs. Unlike the 10% increments adopted by Reynolds et al.
17], the set of cut-offs to be tested is selected from the local
xtremum points on the ROC curve. This guarantees an opti-
al  classiﬁcation, and is better suited to the non-normally
istributed data commonly found in clinical studies, where
he last increments may not be as signiﬁcant as the ﬁrst ones.
anels created with this methodology are robust and easy
o understand, even to users with little mathematical back-
round. They provide efﬁcient classiﬁcation when compared
ith classic methods. We also proposed an approach to reduce
he complexity and increase the speed of the search for larger
ata sets with random forest, efﬁciently limiting information
oss.
Finally, we  showed how to apply the method to answer
 real clinical question that was the outcome prediction for
13 patients following an aneurysmal subarachnoid haemorr-
age. Further validation studies will be necessary to show
hether the ICBT algorithm performs better than classic
ethods. We  could nonetheless show that the classiﬁcation
ower of the resulting panel is superior to that of single
iomarkers. However, to be strictly validated these ﬁnd-
ngs need to be replicated in larger, independent cohorts of
atients. This step is often omitted in biomarker research.
his omission turns out to be even more  critical with panels
f biomarkers which are more  prone to over-ﬁtting the data.
espite the application of cross-validation, proper validation
tudies with external cohorts of patients will be required to
trengthen the conclusions reached through tools such as Pan-
lomiX before the validity of these results will be trusted by
esearchers.The study analyzes 8 biomarkers, however they were all
iscovered using univariate approaches and some of them
ere relatively highly correlated [20]. Multivariate discovery
pproaches [31] are beyond the scope of this paper, but they 9.6 min 1.5 h 15 h 2.0 d 4.4 d
 1.7 min 3.3 min 9.9 min 25 min 1.6 h
could potentially highlight more  interesting combinations of
biomarkers.
In the clinics, a panel of biomarkers would be employed
similarly to a single biomarker. The only difference is that sev-
eral measurements must be performed to reach a result. This
has been demonstrated as feasible using point-of-care test
(POCT) units [32,33]. However, POCT often lack good biomarker
targets, and tool like PanelomiX could hopefully help improv-
ing this situation.
Future prospects include the application of this work-
ﬂow to data sets with more  biomarkers, for instance coming
from gene or protein microarrays or single reaction monitor-
ing experiments. It could also potentially be applied to the
discovery of new biomarkers displaying higher classiﬁcation
performance when combination with other biomarkers.
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